CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Barclays 26th Annual Global Healthcare Conference
Fireside Chat: Tuesday, March 12, 2024 at 4:35 pm ET
Location: Miami, FL
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Fireside Chat: Tuesday, March 26, 2024 at 2:30 pm ET
Location: Virtual
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.56 |
| Daily Change: | -0.08 -4.60 |
| Daily Volume: | 692,904 |
| Market Cap: | US$193.660M |
January 08, 2025 December 27, 2024 September 05, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
